Peptide Alternatives to HRT: What's Being Studied
Peptides and Menopause
75% of menopausal women
Approximately 75% of menopausal women experience vasomotor symptoms. Peptide-based therapies targeting the KNDy neuron pathway now offer nonhormonal alternatives for those who cannot or choose not to use estrogen.
Lehman et al., Endocrinology, 2010
Lehman et al., Endocrinology, 2010
View as imageHormone replacement therapy (HRT) remains the most effective treatment for menopausal vasomotor symptoms. It also reduces osteoporosis risk, improves urogenital atrophy, and may benefit cardiovascular health when started within the first decade after menopause. But HRT is not an option for every woman. Breast cancer survivors, women with a history of venous thromboembolism, and those with certain cardiovascular risk profiles face contraindications. Others simply prefer not to take exogenous estrogen. For a complete picture of the hormonal changes driving these symptoms, see How Peptide Hormones Change During Menopause: The Full Cascade.
This gap has driven research into peptide-based alternatives that target specific pathways disrupted by menopause without replacing estrogen directly. The most clinically advanced approach targets KNDy neurons, a group of hypothalamic cells that use three neuropeptides (kisspeptin, neurokinin B, and dynorphin) to regulate both reproductive function and body temperature. Other peptide drugs already approved for postmenopausal conditions (teriparatide for osteoporosis, calcitonin for bone protection) address specific consequences of estrogen loss rather than the hormonal cascade itself.
Key Takeaways
- KNDy (kisspeptin/neurokinin B/dynorphin) neurons in the hypothalamic arcuate nucleus become hyperactive after menopause, driving both GnRH pulse disruption and vasomotor symptoms (Lehman et al., 2010)
- Fezolinetant, the first NK3 receptor antagonist, was FDA-approved in May 2023 for moderate to severe hot flashes, reducing their frequency by approximately 60% in Phase 3 trials
- Kisspeptin modulates GnRH pulsatility and is being studied as a potential tool for restoring reproductive axis signaling, though its therapeutic role in menopause remains preclinical
- Teriparatide (PTH 1-34) reduced vertebral fractures by 65% in postmenopausal women with osteoporosis in the landmark Neer et al. (2001) trial
- Abaloparatide, a PTHrP analog, reduced vertebral fractures by 86% versus placebo over 18 months in postmenopausal women (Miller et al., 2016)
- No peptide therapy replicates the full spectrum of HRT benefits; each targets a specific symptom or consequence of estrogen loss
The KNDy Neuron Pathway: Why Menopause Causes Hot Flashes
The connection between estrogen loss and hot flashes was unexplained for decades. The discovery of KNDy neurons provided the mechanistic link.
Lehman et al. (2010) published a foundational review establishing that a population of neurons in the hypothalamic arcuate nucleus co-expresses three neuropeptides: kisspeptin, neurokinin B (NKB), and dynorphin. These KNDy neurons act as the central pulse generator for gonadotropin-releasing hormone (GnRH), controlling the rhythmic release of reproductive hormones.[1]
The critical finding is that KNDy neurons are regulated by estrogen through negative feedback. When estrogen levels are adequate, estrogen receptors on KNDy neurons suppress their activity, maintaining normal GnRH pulse frequency. When estrogen drops at menopause, this brake is removed. KNDy neurons become hyperactive: they hypertrophy, upregulate kisspeptin and NKB expression, and downregulate dynorphin (the inhibitory peptide in the triad).[1]
The thermoregulatory link comes from the anatomical overlap between KNDy neurons and the hypothalamic thermoregulatory center. Navarro et al. (2015) described the integrated hypothalamic tachykinin-kisspeptin system and showed that NKB released by hyperactive KNDy neurons directly affects neurons in the preoptic area that control body temperature. The result is inappropriate activation of heat dissipation responses: peripheral vasodilation, sweating, and the subjective sensation of a hot flash.[2]
This mechanism explains why hot flashes correlate with LH pulses (both are driven by KNDy neuron firing), why estrogen replacement stops them (it restores the negative feedback brake), and why targeting the NKB/NK3R axis provides a nonhormonal solution. For a deeper look at kisspeptin's specific role in vasomotor symptoms, see Kisspeptin and Hot Flashes: A Peptide Approach to Vasomotor Symptoms.
Fezolinetant: The First Peptide-Pathway Drug for Hot Flashes
Fezolinetant (Veozah) became the first NK3 receptor antagonist approved by the FDA in May 2023 for moderate to severe vasomotor symptoms due to menopause. While fezolinetant is a small molecule (not a peptide itself), it works by blocking the peptide signaling pathway that drives hot flashes: specifically, it prevents NKB from activating the NK3 receptor on KNDy neurons, reducing their hyperactivity.
The BRIGHT SKY clinical program enrolled over 3,000 women across three Phase 3 trials:
- SKYLIGHT 1 and 2 (pivotal efficacy trials): fezolinetant 45 mg once daily reduced moderate-to-severe hot flash frequency by approximately 60% at 12 weeks compared to placebo. It also reduced hot flash severity.
- SKYLIGHT 4 (long-term safety): characterized the safety profile over 52 weeks, identifying hepatotoxicity as a rare but serious concern
In January 2025, the FDA added a warning about rare occurrences of serious liver injury with fezolinetant, including cases requiring liver transplantation. This safety signal has not led to withdrawal but requires liver function monitoring.
For a dedicated analysis of fezolinetant's mechanism and clinical data, see Fezolinetant: The Neurokinin B Antagonist That Treats Hot Flashes.
Elinzanetant, a dual NK1/NK3 receptor antagonist, received FDA approval in early 2025 for vasomotor symptoms and may also improve sleep disturbances, since NK1 receptor signaling affects sleep architecture. This dual-receptor approach represents a second generation of KNDy-pathway targeting.
Kisspeptin: Upstream Regulator Under Investigation
Kisspeptin is the peptide that sits atop the reproductive hormone cascade. It activates GnRH neurons through the GPR54 receptor, triggering the downstream release of LH and FSH. Skorupskaite et al. (2014) reviewed the kisspeptin-GnRH pathway in human reproductive health, documenting its role as the master switch for puberty onset, menstrual cycle regulation, and reproductive function.[3]
Tena-Sempere (2010) reviewed kisspeptin signaling in the brain and highlighted that kisspeptin neurons are estrogen-sensitive, with expression patterns that shift dramatically based on circulating estrogen levels. In postmenopausal women, kisspeptin expression in the arcuate nucleus increases markedly, contributing to the elevated GnRH and gonadotropin levels that characterize menopause.[4]
The therapeutic question is whether manipulating kisspeptin signaling could modulate the menopausal transition. Kisspeptin agonists have been studied primarily in reproductive medicine: Abbara et al. (2015) demonstrated that kisspeptin-54 injection effectively triggered oocyte maturation in IVF patients at high risk of ovarian hyperstimulation syndrome, providing a safer alternative to hCG triggers.[5]
Whether kisspeptin antagonists could reduce hot flashes by dampening KNDy neuron output has been proposed but not tested in clinical trials. The NKB/NK3R approach (fezolinetant) reached the market first because NKB antagonism specifically targets the thermoregulatory output of KNDy neurons without disrupting the reproductive axis entirely. Kisspeptin antagonism would have broader effects on GnRH pulsatility, which could create unwanted reproductive and metabolic consequences. For more on kisspeptin's role in reproductive signaling, see Kisspeptin and GnRH: How One Peptide Controls Your Reproductive Hormones.
Peptide Drugs for Postmenopausal Osteoporosis
While KNDy-pathway research targets vasomotor symptoms, several FDA-approved peptide drugs already address another major consequence of estrogen loss: bone density decline.
Teriparatide (Forteo)
Teriparatide is a recombinant fragment of parathyroid hormone (amino acids 1-34). In the landmark trial by Neer et al. (2001), published in the New England Journal of Medicine, teriparatide reduced new vertebral fractures by 65% and nonvertebral fractures by 53% in postmenopausal women with prior vertebral fractures. The 20 mcg daily subcutaneous dose increased lumbar spine bone mineral density by 9.7% and femoral neck BMD by 2.8% over a median treatment period of 21 months.[6]
Teriparatide works through a counterintuitive mechanism: parathyroid hormone continuously elevated breaks down bone, but intermittent pulsatile exposure (a daily injection) preferentially stimulates osteoblast activity, producing net bone formation. This anabolic effect distinguishes it from antiresorptive agents like bisphosphonates.
Abaloparatide (Tymlos)
Abaloparatide is a synthetic analog of parathyroid hormone-related peptide (PTHrP). Leder et al. (2015) published the dose-response data showing that abaloparatide increased lumbar spine BMD by 6.7% and total hip BMD by 2.6% over 24 weeks in postmenopausal women with osteoporosis.[7]
Miller et al. (2016) published the pivotal ACTIVE trial in JAMA, showing that abaloparatide reduced new vertebral fractures by 86% and nonvertebral fractures by 43% versus placebo over 18 months. Compared to teriparatide in the same trial, abaloparatide produced similar vertebral fracture reduction with potentially lower hypercalcemia risk.[8]
For a head-to-head comparison of these two peptide drugs, see How Peptide Drugs for Osteoporosis Compare: Teriparatide vs Abaloparatide.
Calcitonin
Calcitonin, a 32-amino-acid peptide hormone produced by thyroid C-cells, has antiresorptive effects on bone. Salmon calcitonin (nasal spray or injection) was previously used for postmenopausal osteoporosis, though its use has declined due to modest efficacy compared to newer agents and a potential cancer signal that led to European market withdrawal. It remains available in the US. See Calcitonin: The Bone-Protecting Peptide Hormone from Your Thyroid for the full evidence review.
What Peptides Cannot Replace
No current peptide therapy replicates the full spectrum of HRT benefits. This is a critical distinction for understanding where peptide alternatives fit:
| Menopausal Domain | HRT | Peptide Alternatives |
|---|---|---|
| Vasomotor symptoms | Highly effective | Fezolinetant (~60% reduction) |
| Urogenital atrophy | Effective (local or systemic) | No peptide alternative |
| Bone density | Protective | Teriparatide/abaloparatide (anabolic) |
| Cardiovascular (early menopause) | Potentially protective | No peptide alternative |
| Mood/cognition | Variable benefit | No peptide alternative |
| Sleep disturbances | Indirect improvement | Elinzanetant (NK1/NK3 dual) |
The peptide approach is inherently modular: each drug targets one specific pathway. HRT, by replacing the missing hormone itself, addresses multiple downstream effects simultaneously. The trade-off is that HRT also carries risks (breast cancer with combined estrogen-progestin, thromboembolic events) that pathway-specific peptide drugs avoid.
Emerging Directions
Several peptide-related approaches are in early-stage research for menopausal symptoms:
Kisspeptin-based diagnostics. Rather than as a therapeutic, kisspeptin challenge tests are being explored as diagnostic tools to assess hypothalamic-pituitary-gonadal axis function during the menopausal transition. The magnitude of LH response to kisspeptin injection could help predict vasomotor symptom severity or response to specific treatments.
GnRH pulsatility restoration. Pulsatile GnRH administration has been used for decades in reproductive endocrinology to restore normal gonadotropin secretion. Whether controlled pulsatile GnRH could modulate the menopausal transition differently from continuous GnRH agonist suppression is an area of theoretical interest but limited clinical investigation.
Oxytocin for mood and sleep. Intranasal oxytocin has been studied for anxiety, depression, and sleep quality in various populations. Whether it offers specific benefits for menopausal mood disturbances has not been adequately tested, though the biological rationale exists given oxytocin's anxiolytic and sleep-promoting central effects.
Next-generation NKB pathway drugs. Beyond fezolinetant and elinzanetant, other NK3R antagonists and potentially NK1R-selective compounds are in development. The goal is to optimize the balance between vasomotor symptom efficacy, sleep improvement, and hepatic safety.
The Bottom Line
Peptide-based alternatives to HRT target specific menopausal pathways rather than replacing estrogen broadly. The KNDy neuron pathway has yielded the first FDA-approved nonhormonal therapy for hot flashes (fezolinetant, 2023), while peptide drugs like teriparatide and abaloparatide address postmenopausal osteoporosis through bone-anabolic mechanisms. No single peptide therapy replaces the full-spectrum benefits of HRT, but for women with contraindications to estrogen, these targeted approaches offer evidence-based alternatives for specific symptoms.